BRAIN Initiative: Development of Novel Tools to Probe Cell-Specific and Circuit-Specific Processes in Human and Non-Human Primate Brain (UG3/UH3 Clinical Trial Optional) | RFA MH 19 135

Opportunity Information: Apply for RFA MH 19 135

The BRAIN Initiative funding opportunity titled "Development of Novel Tools to Probe Cell-Specific and Circuit-Specific Processes in Human and Non-Human Primate Brain (UG3/UH3 Clinical Trial Optional)" supports the creation and rigorous validation of next-generation neurotechnology designed for large brains that are closer to humans in structure and function. The core motivation is practical: major progress in treating brain disorders is limited because current methods cannot monitor and manipulate neural circuits in ways that are both safe and minimally invasive. The opportunity is framed around the idea that understanding and eventually correcting dysfunctional brain circuitry will require tools that can reliably target specific cell types and specific circuits, rather than broadly affecting large regions of the brain.

A central theme of the announcement is translation beyond traditional lab models. Over the last decade, neuroscience has produced many powerful tools, especially under the broader BRAIN Initiative, but most were built and optimized for small model organisms such as rodents, fish, and flies. While those systems remain crucial for discovery, they do not fully capture the challenges of delivering and controlling interventions in large, complex brains. This program aims to push tool development into human and non-human primate contexts, where issues like delivery depth, tissue scale, immune responses, distribution patterns, and access constraints become far more relevant. The opportunity emphasizes that tools proven in small animals often need substantial redesign and testing before they can work effectively and predictably in larger brains.

The types of projects encouraged include both genetic and non-genetic approaches that enable precise delivery of genes, proteins, or chemicals to defined neuronal or non-neuronal cell populations, as well as approaches that preferentially engage particular neural circuits. Examples at a high level include improved viral or other vector-based delivery strategies, molecular targeting systems that achieve higher specificity than current methods, and technologies that can label, trace, track, monitor, or manipulate activity in a cell-type or circuit-selective manner. The solicitation also highlights the broader goal of removing key barriers that currently slow or prevent the development of gene therapy-style interventions for the brain, including challenges related to delivery efficiency, targeting accuracy, and safe deployment.

A strong application is expected to go beyond proposing an interesting tool concept and instead lay out a clear plan to validate that the tool actually works as intended in the relevant large-brain setting. Validation is treated as essential, not optional. In practice, that means applicants should propose credible, measurable benchmarks for performance such as specificity (how well the tool hits the intended cell type or circuit), sensitivity (how reliably it detects or manipulates the target), spatial coverage (how well it performs across relevant brain volumes), reproducibility, and safety or tolerability where appropriate. Because the funding announcement is focused on enabling future clinical impact, projects that explicitly address obstacles to eventual clinical translation, such as minimally invasive delivery routes and predictable targeting, fit well within the stated goals.

The award uses a UG3/UH3 cooperative agreement structure and is labeled "Clinical Trial Optional." The UG3/UH3 format is typically designed for milestone-driven programs where an initial phase supports early development and feasibility work (UG3), followed by a second phase that supports expanded development, optimization, and validation (UH3) once predefined milestones are met. The cooperative agreement mechanism also generally implies substantial involvement from NIH program staff during the life of the award, with a more collaborative and milestone-oriented management style than a standard research grant.

Eligibility is broad and includes many organization types across government, academia, nonprofits, and industry. Eligible applicants listed include state, county, city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments and other tribal organizations; public housing authorities/Indian housing authorities; nonprofits with or without 501(c)(3) status; for-profit organizations (other than small businesses) and small businesses; and other categories. The announcement also explicitly notes additional eligible applicants such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions, Hispanic-serving Institutions, Historically Black Colleges and Universities, Tribally Controlled Colleges and Universities, faith-based or community-based organizations, eligible federal agencies, non-domestic (non-U.S.) entities, regional organizations, and U.S. territories or possessions. This broad eligibility reflects the technical nature of the work and the expectation that meaningful progress may require multidisciplinary teams spanning neurobiology, gene delivery, engineering, chemistry, imaging, computation, and clinical or translational expertise.

Key administrative details in the source information include the agency (National Institutes of Health), the funding opportunity number (RFA MH 19 135), and the funding instrument type (cooperative agreement). The original closing date listed is 2021-05-27, and the opportunity was created on 2018-08-03. Multiple CFDA numbers are associated with the program (93.173, 93.213, 93.242, 93.273, 93.279, 93.286, 93.313, 93.853, 93.865, 93.866, 93.867), reflecting the multi-institute nature of BRAIN-related funding across NIH.

Overall, the opportunity is best understood as a targeted push to create the kinds of precise, scalable, and validated neurotechnologies that can function in large brains and ultimately support new ways to study and treat brain disorders. The emphasis on cell-type and circuit-level specificity, combined with expectations for real-world validation and attention to delivery barriers, signals that NIH is looking for tools that are not only innovative but also plausibly usable in the complex biological and practical environment that human-focused neuroscience demands.

• The National Institutes of Health in the education, health, income security and social services sector is offering a public funding opportunity titled "BRAIN Initiative: Development of Novel Tools to Probe Cell-Specific and Circuit-Specific Processes in Human and Non-Human Primate Brain (UG3/UH3 Clinical Trial Optional)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.173, 93.213, 93.242, 93.273, 93.279, 93.286, 93.313, 93.853, 93.865, 93.866, 93.867.
• This funding opportunity was created on 2018-08-03.
• Applicants must submit their applications by 2021-05-27. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for RFA MH 19 135

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: